

ATTY. DOCKET NO: 4-32702A US-PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

JAN 08 2008

IN RE PCT NATIONAL STAGE APPLICATION OF

KUDARAVALLI ET AL.

U.S. APPLICATION NO: 10/529,613

35 U.S.C. §371 DATE: June 8, 2005

FOR: METHODS TO TREAT CHOLESTEROL ELEVATIONS DURING
IMMUNOSUPPRESSANT THERAPY**MAIL STOP: Amendment**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement of May 7, 2007, Applicants elect the claims of Group II, claims 6-10 and 16 (in part), drawn to methods of determining the degree of cholesterol due to an immunosuppressive by a SNP at -31 of IL-1 β . This election is made without traverse.

In addition, Applicants further elect the species of everolimus as the immunosuppressive medication recited in claims 6, 7 and 8. Everolimus is specifically recited in claim 9. This election is also made without traverse.

Applicants do not believe that a species election is needed for the alternative treatment of claim 10. Should a species election be required, Applicants elect the HMG-CoA Reductase Inhibitor Fluvastatin (LESCOL™)

Applicants believe that this election is timely made. However, if it is deemed that additional fees are required, the Commissioner is authorized to charge Deposit Account No. 19-0134 in the name of Novartis for any fees due.

Applicants reserve the right to prosecute the subject matter of any non-elected claim groups in one or more divisional applications.

An early and favorable action on the merits is respectfully requested. Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,



John Prince, Ph.D.
Attorney for Applicants
Reg. No. 43,019

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3346

Date: May 24, 2007